Form 4: Cryoport's Chief Scientific Officer, Mark W. Sawicki, Reports Stock Sale
SEC Form 4 Filing
Mark W. Sawicki, Chief Scientific Officer of Cryoport, Inc., reported the sale of 1,349 shares of common stock on March 24, 2025, to cover taxes due upon vesting of restricted stock rights.
Summary
- On March 24, 2025, Mark W. Sawicki, the Chief Scientific Officer of Cryoport, Inc. (CYRX), sold 1,349 shares of common stock.
- The sale was executed at a price of $6.9416 per share.
- This transaction was reported on a Form 4 filing with the SEC.
- Following the transaction, Sawicki directly owns 84,087 shares of Cryoport's common stock.
- The sale was conducted to cover taxes due upon the vesting of restricted stock rights, in accordance with the Issuer's policies.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine transaction related to tax obligations and doesn't necessarily reflect a positive or negative outlook on the company.
Industry Context
This is a routine disclosure of insider trading activity. It is common for executives to sell shares to cover tax obligations related to vesting equity.
Key Dates
| Date | Description |
|---|---|
| 03/24/2025 | Date of stock sale transaction. |
| 03/26/2025 | Date of signature on the SEC filing. |
Keywords
Cryoport, CYRX, Mark Sawicki, Form 4, SEC Filing, Stock Sale, Chief Scientific Officer, Beneficial Ownership, Restricted Stock Rights, Tax Obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.